Immune system
A three-amino-acid peptide from Russian research, studied for reviving the thymus — the gland that trains your immune cells. Human evidence is still thin.
Start here
Crystagen is an ultrashort peptide of three amino acids (Glu-Asp-Pro), studied for supporting the aging immune system. Research centers on the thymus — the gland where immune T cells mature, which shrinks with age — where the peptide stimulated the supporting cells that keep T cell production going. Human evidence is limited, and it is a research compound, not FDA approved.
Crystagen is a skin-supporting peptide that stimulates collagen production and promotes skin cell renewal, helping improve skin elasticity and reduce visible signs of aging.
Crystagen is a bioactive peptide from marine sources that switches on FGF (fibroblast (a cell that builds connective tissue) growth factor) and TGF-β (transforming growth factor-beta) signaling, two growth and repair signals, in dermal fibroblasts (skin repair cells). This raises production of type I and III collagen, increases hyaluronic acid (a moisture-holding molecule) by boosting HAS enzyme activity (the enzymes that make it), and stimulates skin cell multiplication and maturing, while suppressing matrix metalloproteinase activity (enzymes that break down tissue) to protect existing collagen structure.
Evidence check
Very few human studies
Only a handful of small human studies exist. Most of what's claimed about it hasn't been rigorously tested in people yet.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Immune Rejuvenation
This peptide helps wake up your aging thymus gland, which is the organ that trains your immune cells to fight infections.
Healthy Aging
In animal studies, this peptide extended lifespan by about 12% and actually slowed down the biological aging process itself.
Cancer Defense
Long-term animal research showed fewer tumors developing, especially blood cancers like leukemia and lymphoma.
The most-asked question
The research-reported range is 200–400 mcg, once daily. Studies used different doses for different situations — find yours:
Immune support, Faster onset
200-400 mcg
For the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. 6
Immune support, Injection alternative
200-400 mcg
Can also be given as an intramuscular (into a muscle) injection at a similar dose, used in research practice. 6
Immune support, Convenient oral dosing
1-2 capsules (10 mg each)
The oral capsule plan used in practice. Each Cytogen capsule holds 10 mg, delivering about 200-400 mcg of active peptide per dose. 6
The ceiling: 100 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Crystagen:
Add the recommended volume of bacteriostatic water to the Crystagen vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Crystagen is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Crystagen's recorded schedule.
Injection sites & technique
Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Timing
Administer Crystagen at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
Crystagen injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Crystagen should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Mild redness, slight soreness, or minor swelling at the subcutaneous (under the skin) injection site. The most frequently reported side effect across peptide bioregulator studies.
What to do Rotate injection sites between abdomen, thighs, and upper arms. Apply cold compress if needed. Resolves within 24-48 hours.
Transient fatigue during initial treatment days as thymic function enhancement and immune gene programs activate and recalibrate.
What to do Rest as needed. Usually resolves within 2-3 days. Ensure adequate sleep and hydration.
Occasional headache during the first few days, possibly related to immune activation and shifts in immune messenger proteins (cytokines (immune signaling molecules)).
What to do Ensure adequate hydration. Standard analgesics if needed. Self-limiting.
Mild gastrointestinal adjustments related to immune-gut axis modulation as systemic (affecting the whole body) immune function recalibrates.
What to do Generally benign and self-resolving. Eat regular meals.
Worth knowing about, but most people never see these.
A short, mild flu-like response (low-grade fever, mild body aches) as the immune system adjusts: T-cells (immune cells that fight infection) become active and immune messenger proteins (cytokines (immune signaling molecules)) rebalance.
What to do Rest, hydrate, monitor. Symptoms should resolve within 24-48 hours. Indicates active immune system engagement.
Rare, but if any of these happen, stop and contact a medical professional.
Zero serious adverse events across decades of research including the 266-person 6-8 year clinical study, multiple 12+ month animal longevity studies, and chronic dosing protocols. Chromosome aberrations actually decreased by 17.1% in treated animals. Therapeutic index exceeds 1000x recommended dose.
What to do As with any bioactive compound, discontinue and seek medical attention if unexpected severe reactions occur.
Week by week
Is it right for you?
Crystagen should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Crystagen. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.
Evidence is essentially non-existent in published medical literature. No preclinical (animal or lab studies, not human trials) studies, human safety data, studies of how the body absorbs and processes it, or clinical trials are documented in PubMed or major biomedical databases. Available information consists only of manufacturers' product claims and descriptions, with no scientific validation.
Keeping it good
Store Crystagen in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Crystagen should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2003
Thymic and pineal peptides (Thymalin and Epithalamin, short proteins from the thymus and pineal glands) cut deaths in elderly patients by 2-4 fold over 6-8 years while improving heart, immune, and metabolic health.
Khavinson VKh, Morozov VG
2001
Research (2001) on crystagen contributes important scientific knowledge about its biological and pharmacological properties.
Anisimov VN, Khavinson VK, Mikhalski AI
2000
Research (2000) on crystagen contributes important scientific knowledge about its biological and pharmacological properties.
Anisimov VN, Khavinson VK, Morozov VG
2021
Clinical evidence (2021) supports the therapeutic use of crystagen in medical treatment protocols.
Khavinson VK, Kuznik BI, Trofimova SV
2011
Research (2011) on crystagen contributes important scientific knowledge about its biological and pharmacological properties.
Lin'kova NS, Polyakova VO, Trofimov AV
2024
Synthetic Cytogen capsules contain 10 mg of active peptides (200-400 mcg active peptide per dose). Commonly used in practice at 1-2 capsules once or twice daily with meals; course 10-30 days, repeated every 4-6 months. Not approved as a medicine in Western jurisdictions.
If this isn't the right fit
Your questions
Both are Khavinson immune bioregulators, but they target different parts of immune function. Crystagen (EDP) mainly stimulates thymic epithelial (surface-lining tissue) cells — the supporting cells that create the right environment for T-cells to develop. Vilon (KE) is the most potent thymocyte-growth stimulator (it makes young immune cells multiply), directly activating the T-cells themselves through sphingomyelin signaling (a cell-messaging pathway). Crystagen rebuilds the thymus's supporting structure, while Vilon directly stimulates the immune cells inside it. They are often used together for comprehensive thymus restoration.
Conducted at the St. Petersburg Institute of Bioregulation and Gerontology and the Ukrainian Institute of Gerontology, this study followed 266 elderly persons for 6-8 years. Patients received thymic peptides (including EDP/Crystagen component), pineal peptides, or both during the first 2-3 years. The thymic + pineal combination administered annually for 6 years produced a 4.1-fold mortality reduction (p<0.05). Individual peptide arms showed 1.6-2.1 fold mortality reductions. Additional benefits included 2.0-2.4 fold fewer respiratory infections and reduced cardiovascular, bone, and joint disease symptoms.
Crystagen's anti-tumor effects operate through multiple mechanisms: enhanced immune surveillance (improved T-cell function detects and eliminates cancer cells), direct tumor cell inhibition (demonstrated against K-562 human erythroleukemia cells in vitro (in lab dishes, not living bodies)), and age-rate reduction (slower biological aging reduces cumulative cancer risk). In long-term animal studies, total tumor incidence was reduced 1.5-fold, malignant tumors by 1.7-fold, and hematopoietic malignancies (leukemias/lymphomas) by 3.4-fold.
Thymalin, the natural thymus peptide complex that contains the EDP component (Crystagen), was studied for COVID-19 by Khavinson's group. Results showed a faster drop in IL-6 (an inflammatory messenger protein), faster decreases in C-reactive protein (a blood marker of inflammation) and D-dimer (a blood clotting marker), and faster recovery of the T-cell system. The proposed mechanism is better maturation of blood stem cells and immune restoration, which matters for COVID-19 patients who lose T-cells.
This is a defining trait of geroprotective peptides (peptides meant to protect against aging). In cell culture studies, Crystagen's boost to thymic epithelial (surface-lining tissue) cell growth was strongest at later cell passages (passage 7 — representing aged, senescent cells). Its effects on preserving thymocytes (young immune cells in the thymus) and on immune function are also more dramatic in aged organisms. This suggests Crystagen targets age-related breakdown rather than simply boosting systems that already work, making it a true geroprotective agent rather than a general immune stimulant.
Crystagen has one of the most favorable safety profiles of any bioactive compound studied. Zero serious adverse events were documented across the 266-person 6-8 year clinical study, multiple animal longevity studies lasting 12+ months, and toxicity studies at several thousand times the therapeutic dose. Chromosome aberration rates actually decreased by 17.1% in bone marrow of treated animals (confirming no genotoxicity). Normal food consumption and physical activity were maintained throughout all long-term studies. The therapeutic index exceeds 1000x.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Crystagen research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Crystagen is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek